Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 20;41(24):4045-4053.
doi: 10.1200/JCO.22.02208. Epub 2023 Jun 2.

The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer

Collaborators, Affiliations

The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer

Joseph A Flores-Toro et al. J Clin Oncol. .

Abstract

Data-driven basic, translational, and clinical research has resulted in improved outcomes for children, adolescents, and young adults (AYAs) with pediatric cancers. However, challenges in sharing data between institutions, particularly in research, prevent addressing substantial unmet needs in children and AYA patients diagnosed with certain pediatric cancers. Systematically collecting and sharing data from every child and AYA can enable greater understanding of pediatric cancers, improve survivorship, and accelerate development of new and more effective therapies. To accomplish this goal, the Childhood Cancer Data Initiative (CCDI) was launched in 2019 at the National Cancer Institute. CCDI is a collaborative community endeavor supported by a 10-year, $50-million (in US dollars) annual federal investment. CCDI aims to learn from every patient diagnosed with a pediatric cancer by designing and building a data ecosystem that facilitates data collection, sharing, and analysis for researchers, clinicians, and patients across the cancer community. For example, CCDI's Molecular Characterization Initiative provides comprehensive clinical molecular characterization for children and AYAs with newly diagnosed cancers. Through these efforts, the CCDI strives to provide clinical benefit to patients and improvements in diagnosis and care through data-focused research support and to build expandable, sustainable data resources and workflows to advance research well past the planned 10 years of the initiative. Importantly, if CCDI demonstrates the success of this model for pediatric cancers, similar approaches can be applied to adults, transforming both clinical research and treatment to improve outcomes for all patients with cancer.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Subhashini Jagu

Patents, Royalties, Other Intellectual Property: Richard Roden and Subhashini Jagu (2007): "Multitype HPV Peptide Compositions and Method for Treatment or Prevention of Human Papillomavirus Infection"

Gregory T. Armstrong

Honoraria: Grail

Gregory J. Aune

Consulting or Advisory Role: LumaBridge

Douglas S. Hawkins

Research Funding: Bayer (Inst), Lilly (Inst), Jazz Pharmaceuticals (Inst), Pfizer (Inst)

Lee J. Helman

Leadership: Vuja De Sciences

Stock and Other Ownership Interests: Horizon Therapeutics, AstraZeneca

Consulting or Advisory Role: Oncoheroes Biosciences, Medically Home, HebeCell

Katherine A. Janeway

Honoraria: Foundation Medicine, Takeda

Consulting or Advisory Role: Bayer, Ipsen

Travel, Accommodations, Expenses: Bayer

Charles W. M. Roberts

Stock and Other Ownership Interests: Exo Therapeutics

Consulting or Advisory Role: Exo Therapeutics

Travel, Accommodations, Expenses: Exo Therapeutics

Louis M. Staudt

Patents, Royalties, Other Intellectual Property: Patents and patents pending regarding gene expression profiling in lymphoma that have been licensed by Nanostring and for which I receive royalties

Samuel L. Volchenboum

Stock and Other Ownership Interests: Litmus Health

Consulting or Advisory Role: Accordant, Westat

Travel, Accommodations, Expenses: Sanford Health

Douglas R. Lowy

Patents, Royalties, Other Intellectual Property: I am an inventor of technology that underlies the L1-based prophylactic virus-like particle (VLP) HPV vaccine and technology that underlies an L2-based candidate prophylactic HPV vaccine (Inst), Merck, GlaxoSmithKline

Norman E. Sharpless

Employment: Jupiter Bioventures

Leadership: G1 Therapeutics, Jupiter Bioventures, Nucleus Labs, Karius Inc

Stock and Other Ownership Interests: Karius Inc, Nucleus Radiopharma, Jupiter BioVentures, G1 Therapeutics

Travel, Accommodations, Expenses: American Cancer Society

Open Payments Link: https://openpaymentsdata.cms.gov/physician/250214/

Warren A. Kibbe

Honoraria: Power Medicine

No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
CCDI Working Group structure: The CCDI Working Groups provide important feedback on the crucial areas on which the initiative should focus. The Cohort Working Group is tasked with developing strategies and a series of initiatives (eg, capture historical data and ensure it is accessible and interoperable with the prospective data) to gather data from every patient diagnosed with a pediatric cancer in the United States. The Protocol Working Group provides expert guidance for the MCI screening protocol. The Cross-Cutting Working Group is focused on ensuring the effective collaboration, communication, and coordination of all activities for the CCDI. The Platform Working Group defines a strategy and approach for federating and/or integrating data to enable integrated analytics and incentivize researchers to use the data in new ways. CCDI, Childhood Cancer Data Initiative; MCI, Molecular Characterization Initiative.
FIG 2.
FIG 2.
CCDI activities over the first 3 years: Broad categorical breakdown of the first 3 years of CCDI activities. Roughly equal funding contributions have been made to each of these objectives over the first 3 years. CCDI, Childhood Cancer Data Initiative; EHR, electronic health record; NCCR, National Childhood Cancer Registry; RPG, research project grant.

Comment in

References

    1. American Cancer Society: Cancer Facts & Figures 2022. Atlanta, GA, American Cancer Society, 2022.
    1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66:7-30, 2016 - PubMed
    1. Gibson TM, Mostoufi-Moab S, Stratton KL, et al. : Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: A report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 19:1590-1601, 2018 - PMC - PubMed
    1. Moke DJ, Tsai K, Hamilton AS, et al. : Emerging cancer survival trends, disparities, and priorities in adolescents and young adults: A California Cancer Registry-based study. JNCI Cancer Spectr 3:pkz031, 2019 - PMC - PubMed
    1. Jemal A, Siegel RL, Xu J, et al. : Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010 - PubMed

Publication types